These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32372314)

  • 1. ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis.
    Liu H; Zureikat A
    Ann Surg Oncol; 2020 Oct; 27(10):3961-3962. PubMed ID: 32372314
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy.
    Al Abbas AI; Hogg ME
    Ann Surg Oncol; 2020 Jun; 27(6):2015-2016. PubMed ID: 32172332
    [No Abstract]   [Full Text] [Related]  

  • 3. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
    Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.
    Al Abbas AI; Zenati M; Reiser CJ; Hamad A; Jung JP; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2020 Jun; 27(6):2007-2014. PubMed ID: 31898105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
    Adam MA; Paniccia A
    Ann Surg Oncol; 2021 Jul; 28(7):3808-3809. PubMed ID: 33475885
    [No Abstract]   [Full Text] [Related]  

  • 7. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.
    Liu H; Zenati MS; Rieser CJ; Al-Abbas A; Lee KK; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2020 Oct; 27(10):3950-3960. PubMed ID: 32318949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
    Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
    Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.
    Murthy P; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):907-908. PubMed ID: 31823171
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.
    Alva-Ruiz R; Truty MJ
    Ann Surg Oncol; 2022 Mar; 29(3):1592-1593. PubMed ID: 34705142
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
    Kamarajah SK; Dahdaleh F
    Ann Surg Oncol; 2021 Apr; 28(4):1906-1907. PubMed ID: 33389290
    [No Abstract]   [Full Text] [Related]  

  • 16. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
    Williams JL; Kadera BE; Nguyen AH; Muthusamy VR; Wainberg ZA; Hines OJ; Reber HA; Donahue TR
    J Gastrointest Surg; 2016 Jul; 20(7):1331-42. PubMed ID: 27114246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients.
    Imamura T; Okamura Y; Sugiura T; Yamamoto Y; Ito T; Ashida R; Ohgi K; Ohtsuka S; Uesaka K
    Ann Surg Oncol; 2021 Oct; 28(11):6236-6237. PubMed ID: 33586063
    [No Abstract]   [Full Text] [Related]  

  • 19. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma.
    Mehtsun WT; Hashimoto DA; Ferrone CR
    Adv Surg; 2019 Sep; 53():253-269. PubMed ID: 31327451
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
    Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
    Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.